Taiwan Advanced Nanotech Inc.
Taiwan Advanced Nanotech Inc. engages in the development, manufacturing, and sales of various functional nanoparticles and automated nucleic acid extraction equipment in Taiwan. The company provides automated extraction instruments; nucleic acid extraction kit that extracts DNA/RNA from samples of blood, cell, tissue, plant, bacteria, virus, etc.; consumables, such as spin tips and deep well plat… Read more
Taiwan Advanced Nanotech Inc. (6797) - Net Assets
Latest net assets as of June 2025: NT$888.69 Million TWD
Based on the latest financial reports, Taiwan Advanced Nanotech Inc. (6797) has net assets worth NT$888.69 Million TWD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$1.34 Billion) and total liabilities (NT$450.26 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$888.69 Million |
| % of Total Assets | 66.37% |
| Annual Growth Rate | 46.85% |
| 5-Year Change | 6.25% |
| 10-Year Change | N/A |
| Growth Volatility | 216.62 |
Taiwan Advanced Nanotech Inc. - Net Assets Trend (2019–2024)
This chart illustrates how Taiwan Advanced Nanotech Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Taiwan Advanced Nanotech Inc. (2019–2024)
The table below shows the annual net assets of Taiwan Advanced Nanotech Inc. from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$1.01 Billion | -15.59% |
| 2023-12-31 | NT$1.19 Billion | -21.06% |
| 2022-12-31 | NT$1.51 Billion | +18.55% |
| 2021-12-31 | NT$1.28 Billion | +34.51% |
| 2020-12-31 | NT$948.11 Million | +543.15% |
| 2019-12-31 | NT$147.42 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Taiwan Advanced Nanotech Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 40222000000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | NT$365.62 Million | 36.29% |
| Common Stock | NT$307.32 Million | 30.51% |
| Other Components | NT$334.43 Million | 33.20% |
| Total Equity | NT$1.01 Billion | 100.00% |
Taiwan Advanced Nanotech Inc. Competitors by Market Cap
The table below lists competitors of Taiwan Advanced Nanotech Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Chromocell Therapeutics Corporation
NYSE MKT:CHRO
|
$8.90 Million |
|
JCBNext Berhad Bhd
KLSE:0058
|
$8.91 Million |
|
artnet AG
PINK:ARTZF
|
$8.91 Million |
|
Daewon Co. Ltd
KQ:007680
|
$8.91 Million |
|
Cosmos Health Inc.
NASDAQ:COSM
|
$8.90 Million |
|
Artha Optimum A/S
CO:ARAOPT
|
$8.90 Million |
|
EAST STAR RES.PLC LS-01
F:5MM
|
$8.90 Million |
|
FORIS AG
F:FRS
|
$8.90 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Taiwan Advanced Nanotech Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,193,472,000 to 1,007,375,000, a change of -186,097,000 (-15.6%).
- Net loss of 190,567,000 reduced equity.
- Other comprehensive income decreased equity by 158,999,000.
- Other factors increased equity by 163,469,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$-190.57 Million | -18.92% |
| Other Comprehensive Income | NT$-159.00 Million | -15.78% |
| Other Changes | NT$163.47 Million | +16.23% |
| Total Change | NT$- | -15.59% |
Book Value vs Market Value Analysis
This analysis compares Taiwan Advanced Nanotech Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.44x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 2.50x to 0.44x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | NT$5.74 | NT$14.35 | x |
| 2020-12-31 | NT$32.77 | NT$14.35 | x |
| 2021-12-31 | NT$40.14 | NT$14.35 | x |
| 2022-12-31 | NT$47.92 | NT$14.35 | x |
| 2023-12-31 | NT$39.14 | NT$14.35 | x |
| 2024-12-31 | NT$32.78 | NT$14.35 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Taiwan Advanced Nanotech Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -18.92%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -96.45%
- • Asset Turnover: 0.14x
- • Equity Multiplier: 1.37x
- Recent ROE (-18.92%) is below the historical average (12.53%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -24.83% | -32.12% | 0.49x | 1.59x | NT$-51.34 Million |
| 2020 | 65.20% | 35.96% | 0.91x | 1.99x | NT$523.38 Million |
| 2021 | 49.11% | 32.46% | 0.88x | 1.72x | NT$498.56 Million |
| 2022 | 22.03% | 24.58% | 0.57x | 1.57x | NT$178.01 Million |
| 2023 | -17.44% | -84.76% | 0.14x | 1.50x | NT$-327.53 Million |
| 2024 | -18.92% | -96.45% | 0.14x | 1.37x | NT$-291.30 Million |
Industry Comparison
This section compares Taiwan Advanced Nanotech Inc.'s net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $1,274,214,400
- Average return on equity (ROE) among peers: 6.56%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Taiwan Advanced Nanotech Inc. (6797) | NT$888.69 Million | -24.83% | 0.51x | $8.90 Million |
| Health & Life Co., Ltd. (1781) | $372.58 Million | -4.71% | 1.15x | $12.97 Million |
| Hi-Clearance (1788) | $3.00 Billion | 11.98% | 0.65x | $104.25 Million |
| Radiant Innovation (3373) | $865.89 Million | -3.30% | 0.08x | $18.65 Million |
| Wellell Inc (4106) | $1.31 Billion | 13.81% | 0.24x | $37.12 Million |
| Rossmax International Ltd (4121) | $1.33 Billion | 1.93% | 1.30x | $38.32 Million |
| United Orthopedic (4129) | $1.77 Billion | 7.55% | 0.46x | $300.33 Million |
| Dynamic Medical Technologies (4138) | $1.76 Billion | 11.67% | 0.71x | $39.41 Million |
| Ok Biotech Co Ltd (4155) | $1.30 Billion | 9.66% | 0.71x | $44.61 Million |
| Bioptik Technology (4161) | $717.83 Million | 6.76% | 1.11x | $30.42 Million |
| EPS Bio Technology Corp. (4183) | $309.15 Million | 10.25% | 0.77x | $4.27 Million |